Single-arm study | Pembrolizumab plus Lenvatinib shows potential as first-line treatment for advanced non-clear-cell renal cell carcinoma
17 Jul, 2023 | 13:33h | UTCPembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)